Upgrade to SI Premium - Free Trial

Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c

November 4, 2025 7:04 AM

Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.94), $0.18 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

Categories

Earnings